Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.57 Average Price Target from Brokerages

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) have been assigned an average recommendation of “Buy” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $40.57.

PLRX has been the topic of several analyst reports. Leerink Partnrs raised shares of Pliant Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners initiated coverage on shares of Pliant Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $33.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Pliant Therapeutics in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of Pliant Therapeutics in a report on Friday, September 13th. Finally, Oppenheimer cut their price target on shares of Pliant Therapeutics from $48.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th.

Pliant Therapeutics Trading Down 3.2 %

PLRX stock opened at $15.19 on Friday. The company has a market capitalization of $923.57 million, a PE ratio of -4.94 and a beta of 1.08. Pliant Therapeutics has a one year low of $10.22 and a one year high of $19.62. The company’s 50 day moving average price is $12.96 and its two-hundred day moving average price is $12.69. The company has a debt-to-equity ratio of 0.08, a quick ratio of 14.47 and a current ratio of 14.47.

Pliant Therapeutics (NASDAQ:PLRX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.07). As a group, analysts predict that Pliant Therapeutics will post -3.71 earnings per share for the current fiscal year.

Institutional Trading of Pliant Therapeutics

Hedge funds have recently modified their holdings of the business. Summit Securities Group LLC bought a new stake in shares of Pliant Therapeutics during the 2nd quarter valued at $59,000. SG Americas Securities LLC bought a new stake in shares of Pliant Therapeutics during the 1st quarter valued at $107,000. Atria Investments Inc bought a new stake in shares of Pliant Therapeutics during the 3rd quarter valued at $112,000. Deerfield Management Company L.P. Series C purchased a new position in shares of Pliant Therapeutics in the 2nd quarter worth about $126,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Pliant Therapeutics by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock worth $131,000 after purchasing an additional 4,607 shares during the last quarter. Institutional investors own 97.30% of the company’s stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.